What’s the State of Market Access in Denmark After Five Years with the Danish Medicines Council?

Denmark established the Danish Medicines Council (DMC) back in 2017 to help make assessment of medicines faster, transparent, and more consistent. In a recent Amerisource Bergen article, Flemming Axelsen, MSC, looks back at the past five years of the DMC, explaining its successes, failures, and the lessons that can be gleaned from both.

According to Axelsen, “Before the establishment of DMC, the average time from European Medicines Agency (EMA) approval to first commercial use of a new medicine in Danish hospitals was only 106 days. In 2021, the average time from EMA approval to first commercial use, with cost-effectiveness assessed by DMC, had more than tripled to 321 days. What does this mean for companies developing new medicines for patients in need?”

To read more, click here.

(Source: AmerisourceBergen, September 23^rd, 2022)